PPD161570 (PD-16157; PD 16157) 以剂量依赖性方式抑制PDGF刺激的血管平滑肌细胞增殖，第8天的IC₅₀值为0.3 µM。PD161570也是FGF-1受体抑制剂（FGFR抑制剂）（IC₅₀=39.9 nM）。 PD161570抑制人卵巢癌细胞(A121(p))和过表达人FGF-1受体的Sf9昆虫细胞中FGF-1受体的组成型磷酸化，还可有效抑制碱性成纤维细胞生长因子(bFGF)介导的血管生成。

参考文献

[1]. Hamby JM, et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem. 1997 Jul 18;40(15):2296-303.

[2]. Batley BL, et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1998;62(2):143-50.

[3]. Wolfe A, et al. Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. J Biomol Screen. 2013 Dec;18(10):1234-45.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。